WuXi AppTec is enlisting more lobbyists to represent its interests before Congress, where China hawks have pushed for limits on how the company works with US biotech and pharma companies.
More drug companies are disclosing the potential for clinical trial delays and drug shortages if the US government blacklists a family of WuXi companies used across the biopharma industry.
Rep. Mike Gallagher (R-WI), the lead sponsor of a closely watched bill that would prevent many US biopharma companies from doing business with WuXi and potentially other Chinese biopharma companies, is leaving his post next month, the congressman announced Friday.
WuXi AppTec's 2023 sales largely reliant on the US, report says
Biotech trade association to split with China`s WuXi AppTec
WuXi became a critical partner to biopharma companies
U.S. Legislation Seeking Sanctions on BGI, WuXi Apptec Advances
Senate committee advances bill targeting Chinese manufacturers
WuXi Advanced Therapies (ATU) will manufacture Iovance’s recently approved Amtagvi for advanced melanoma, which was heralded as the first modern cell therapy to secure an approval in solid tumors and also the first approval for a tumor-infiltrating lymphocyte-based therapy.